Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma

To investigate the efficacy of the combination of gemcitabine with capecitabine in the chemotherapy for patients with relapsed or metastatic biliary tract carcinoma. Forty-one patients with unresectable relapsed or metastatic carcinoma of the biliary tract were treated from March 2000 to December 20...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá zhŏngliú zázhì Vol. 30; no. 2; p. 144
Main Authors Yu, Zong-Yang, Ouyang, Xue-Nong, Chen, Zhang-Shu, Li, Jie, Chen, Xi, Xie, Fang-Wei
Format Journal Article
LanguageChinese
Published China 01.02.2008
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - pathology
Bile Ducts, Intrahepatic
Capecitabine
Cholangiocarcinoma - drug therapy
Cholangiocarcinoma - pathology
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Diarrhea - chemically induced
Female
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Follow-Up Studies
Humans
Male
Middle Aged
Nausea - chemically induced
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neutropenia - chemically induced
Remission Induction
Survival Rate
Online AccessGet more information

Cover

More Information
Summary:To investigate the efficacy of the combination of gemcitabine with capecitabine in the chemotherapy for patients with relapsed or metastatic biliary tract carcinoma. Forty-one patients with unresectable relapsed or metastatic carcinoma of the biliary tract were treated from March 2000 to December 2004. The regimen consisted of intravenous administration of gemcitabine plus oral intake of capecitabine every 3 weeks for more than 2 cycles. The parameters including tumor response, clinical benefit rate,survival and safety were observed. Thirty-six patients were valuable and 5 patients were excluded from this series due to various reasons. Eleven patients (30.1%) had a partial response and another 11 patients (30.1%) experieced stable disease with a clinical benefit rates of 61.1%. The median overall survival time and time to progression were 10 months and 6 months, respectively. The one-year survival rate was 40.0%. The adverse events including nausea, diarrhea and hand-foot syndrome, fatigue, neutropenia, throm
ISSN:0253-3766